Association between Moraxella keratitis and advanced glycation end products.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 Apr 2024
05 Apr 2024
Historique:
received:
27
11
2023
accepted:
02
04
2024
medline:
6
4
2024
pubmed:
6
4
2024
entrez:
5
4
2024
Statut:
epublish
Résumé
Diabetes mellitus is recognized as a major predisposing factor for Moraxella keratitis. However, how diabetes mellitus contributes to Moraxella keratitis remains unclear. In this study, we examined Moraxella keratitis; based on the findings, we investigated the impact of advanced glycation end products (AGEs) deposition in the cornea of individuals with diabetic mellitus on the adhesion of Moraxella isolates to the cornea. A retrospective analysis of 27 culture-proven cases of Moraxella keratitis at Ehime University Hospital (March 2006 to February 2022) was performed. Moraxella isolates were identified using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Among the patients, 30.4% had diabetes mellitus and 22.2% had the predominant ocular condition of using steroid eye drops. The species identified were Moraxella nonliquefaciens in 59.3% and Moraxella lacunata in 40.7% of patients. To investigate the underlying mechanisms, we assessed the effects of M. nonliquefaciens adherence to simian virus 40-immortalized human corneal epithelial cells (HCECs) with or without AGEs. The results demonstrated the number of M. nonliquefaciens adhering to HCECs was significantly increased by adding AGEs compared with that in controls (p < 0.01). Furthermore, in the corneas of streptozotocin-induced diabetic C57BL/6 mice treated with or without pyridoxamine, an AGE inhibitor, the number of M. nonliquefaciens adhering to the corneas of diabetic mice was significantly reduced by pyridoxamine treatment (p < 0.05). In conclusion, the development of Moraxella keratitis may be significantly influenced by the deposition of AGEs on the corneal epithelium of patients with diabetes mellitus.
Identifiants
pubmed: 38580798
doi: 10.1038/s41598-024-58659-7
pii: 10.1038/s41598-024-58659-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8024Informations de copyright
© 2024. The Author(s).
Références
Eyre, J. W. A clinical and bacteriological study of diplo-bacillary conjunctivitis. J. Pathol. Bacteriol. 6, 1–13 (1900).
doi: 10.1002/path.1700060102
Perez Vidakovics, M. L. & Riesbeck, K. Virulence mechanisms of Moraxella in the pathogenesis of infection. Curr. Opin. Infect. Dis. 22, 279–285 (2009).
pubmed: 19405217
doi: 10.1097/QCO.0b013e3283298e4e
van den Munckhof, E. H. A. et al. Nasal microbiota dominated by Moraxella spp. Is associated with respiratory health in the elderly population: A case control study. Respir. Res. 21, 181 (2020).
pubmed: 32664929
pmcid: 7362441
doi: 10.1186/s12931-020-01443-8
Hol, C. et al. Moraxella catarrhalis in acute laryngitis: Infection or colonization?. J. Infect. Dis. 174, 636–638 (1996).
pubmed: 8769627
doi: 10.1093/infdis/174.3.636
Murphy, T. F., Brauer, A. L., Grant, B. J. & Sethi, S. Moraxella catarrhalis in chronic obstructive pulmonary disease: Burden of disease and immune response. Am. J. Respir. Crit. Care Med. 172, 195–199 (2005).
pubmed: 15805178
pmcid: 2718466
doi: 10.1164/rccm.200412-1747OC
Vergison, A. Microbiology of otitis media: A moving target. Vaccine 26(Suppl 7), G5–G10 (2008).
pubmed: 19094935
pmcid: 7127463
doi: 10.1016/j.vaccine.2008.11.006
Kao, C., Szymczak, W. & Munjal, I. Meningitis due to Moraxella nonliquefaciens in a paediatric patient: A case report and review of the literature. JMM Case Rep. 4, e005086 (2017).
pubmed: 28348808
pmcid: 5361638
doi: 10.1099/jmmcr.0.005086
Seal, D. V., Barrett, S. P. & McGill, J. I. Aetiology and treatment of acute bacterial infection of the external eye. Br. J. Ophthalmol. 66, 357–360 (1982).
pubmed: 7082605
pmcid: 1039799
doi: 10.1136/bjo.66.6.357
Garg, P., Mathur, U., Athmanathan, S. & Rao, G. N. Treatment outcome of Moraxella keratitis: Our experience with 18 cases—A retrospective review. Cornea 18, 176 (1999).
pubmed: 10090363
doi: 10.1097/00003226-199903000-00006
Berrocal, A. M., Scott, I. U., Miller, D. & Flynn, H. W. Jr. Endophthalmitis caused by Moraxella species. Am. J. Ophthalmol. 132, 788–790 (2001).
pubmed: 11704047
doi: 10.1016/S0002-9394(01)01098-4
Das, S., Constantinou, M., Daniell, M. & Taylor, H. R. Moraxella keratitis: Predisposing factors and clinical review of 95 cases. Br. J. Ophthalmol. 90, 1236–1238 (2006).
pubmed: 16825274
pmcid: 1857441
doi: 10.1136/bjo.2006.095182
Inoue, H. et al. Clinical characteristics and bacteriological profile of Moraxella keratitis. Cornea 34, 1105–1109 (2015).
pubmed: 25970435
doi: 10.1097/ICO.0000000000000470
Leung, A. K. C., Hon, K. L., Wong, A. H. C. & Wong, A. S. Bacterial conjunctivitis in childhood: Etiology, clinical manifestations, diagnosis, and management. Recent Pat. Inflamm. Allergy Drug Discov. 12, 120–127 (2018).
pubmed: 29380707
doi: 10.2174/1872213X12666180129165718
Zafar, H. et al. Clinical characteristics and outcomes of Moraxella keratitis. Cornea 37, 1551–1554 (2018).
pubmed: 30222715
doi: 10.1097/ICO.0000000000001749
Durrani, A. F. et al. Moraxella keratitis: Analysis of risk factors, clinical characteristics, management, and treatment outcomes. Am. J. Ophthalmol. 197, 17–22 (2019).
pubmed: 30201340
doi: 10.1016/j.ajo.2018.08.055
McSwiney, T. J., Knowles, S. J. & Murphy, C. C. Clinical and microbiological characteristics of Moraxella keratitis. Br. J. Ophthalmol. 103, 1704–1709 (2019).
pubmed: 30709811
LaCroce, S. J. et al. Moraxella nonliquefaciens and M. osloensis are important Moraxella species that cause ocular infections. Microorganisms 7, 163 (2019).
pubmed: 31167433
pmcid: 6616425
doi: 10.3390/microorganisms7060163
Takahashi, S. et al. Moraxella species: Infectious microbes identified by use of time-of-flight mass spectrometry. Jpn. J. Ophthalmol. 63, 328–336 (2019).
pubmed: 31273564
doi: 10.1007/s10384-019-00669-4
Hoarau, G. et al. Moraxella keratitis: Epidemiology and outcomes. Eur. J. Clin. Microbiol. Infect. Dis. 39, 2317–2325 (2020).
pubmed: 32648113
doi: 10.1007/s10096-020-03985-7
Kenny, S. E., Puig, M., Salinas, R., Johnson, D. A. & Kheirkhah, A. Moraxella keratitis: A case series. Eye Contact Lens 47, 674–676 (2021).
pubmed: 34520409
doi: 10.1097/ICL.0000000000000839
Study Group of National Surveillance of Infectious Keratitis in Japan. National Surveillance of Infectious Keratitis in Japan--current status of isolates, patient background, and treatment. Nippon Ganka Gakkai Zasshi 110, 961–972 (2006).
Puig, M., Weiss, M., Salinas, R., Johnson, D. A. & Kheirkhah, A. Etiology and risk factors for infectious keratitis in South texas. J. Ophthalmic. Vis. Res. https://doi.org/10.18502/jovr.v15i2.6729 (2020).
doi: 10.18502/jovr.v15i2.6729
pubmed: 32308946
pmcid: 7151511
Almulhim, A., Alkhalifah, M. I., Kalantan, H. & Alsarhani, W. K. Bacterial keratitis: Clinical features, causative organisms, and outcome during a 13 year study period. Cornea 42, 702–707 (2023).
pubmed: 36730384
doi: 10.1097/ICO.0000000000003179
Schultz, R. O., Van Horn, D. L., Peters, M. A., Klewin, K. M. & Schutten, W. H. Diabetic keratopathy. Trans. Am. Ophthalmol. Soc. 79, 180–199 (1981).
pubmed: 7342400
pmcid: 1312182
Datiles, M. B., Kador, P. F., Fukui, H. N., Hu, T. S. & Kinoshita, J. H. Corneal re-epithelialization in galactosemic rats. Invest. Ophthalmol. Vis. Sci. 24, 563–569 (1983).
pubmed: 6841002
Huang, S. P. et al. Aldo-keto reductases in the eye. J. Ophthalmol. 2010, 521204 (2010).
pubmed: 20628518
pmcid: 2902055
Kimura, T. et al. Accumulation of advanced glycation end products of the maillard reaction with age in human hippocampal neurons. Neurosci. Lett. 208, 53–56 (1996).
pubmed: 8731173
doi: 10.1016/0304-3940(96)12537-4
Singh, R., Barden, A., Mori, T. & Beilin, L. Advanced glycation end-products: A review. Diabetologia 44, 129–146 (2001).
pubmed: 11270668
doi: 10.1007/s001250051591
Kaji, Y. et al. Advanced glycation end products in diabetic corneas. Invest. Ophthalmol. Vis. Sci. 41, 362–368 (2000).
pubmed: 10670463
Smuda, M. et al. Comprehensive analysis of maillard protein modifications in human lenses: Effect of age and cataract. Biochemistry 54, 2500–2507 (2015).
pubmed: 25849437
doi: 10.1021/bi5013194
Nagaraj, R. H., Linetsky, M. & Stitt, A. W. The pathogenic role of maillard reaction in the aging eye. Amino Acids 42, 1205–1220 (2012).
pubmed: 20963455
doi: 10.1007/s00726-010-0778-x
Beisswenger, P. J. et al. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44, 824–829 (1995).
pubmed: 7789650
doi: 10.2337/diab.44.7.824
Xu, J. et al. Involvement of advanced glycation end products in the pathogenesis of diabetic retinopathy. Cell. Physiol. Biochem. 48, 705–717 (2018).
pubmed: 30025404
doi: 10.1159/000491897
Zou, C., Wang, S., Huang, F. & Zhang, Y. A. Advanced glycation end products and ultrastructural changes in corneas of long-term Streptozotocin-induced diabetic monkeys. Cornea 31, 1455–1459 (2012).
pubmed: 22695699
doi: 10.1097/ICO.0b013e3182490907
Wan, L. et al. The advanced glycation end-products (AGEs)/ROS/NLRP3 inflammasome axis contributes to delayed diabetic corneal wound healing and nerve regeneration. Int. J. Biol. Sci. 18, 809–825 (2022).
pubmed: 35002527
pmcid: 8741862
doi: 10.7150/ijbs.63219
Shi, L., Yu, X., Yang, H. & Wu, X. Advanced glycation end products induce human corneal epithelial cells apoptosis through generation of reactive oxygen species and activation of JNK and p38 MAPK pathways. PLoS One 8, e66781–e66781 (2013).
pubmed: 23776698
pmcid: 3680386
doi: 10.1371/journal.pone.0066781
Ozer, A. et al. Advanced glycation end products facilitate bacterial adherence in urinary tract infection in diabetic mice. Pathog. Dis. https://doi.org/10.1093/femspd/ftu004 (2014).
doi: 10.1093/femspd/ftu004
pubmed: 25986378
pmcid: 4444075
Reid, G. & Sobel, J. D. Bacterial adherence in the pathogenesis of urinary tract infection: A review. Rev. Infect. dis. 9, 470–487 (1987).
pubmed: 2885910
doi: 10.1093/clinids/9.3.470
Reid, G., Howard, J. & Gan, B. S. Can bacterial interference prevent infection?. Trends Microbiol. 9, 424–428 (2001).
pubmed: 11553454
doi: 10.1016/S0966-842X(01)02132-1
Dingle, T. C. & Butler-Wu, S. M. MALDI-TOF mass spectrometry for microorganism identification. Clin. Lab. Med. 33, 589–609 (2013).
pubmed: 23931840
doi: 10.1016/j.cll.2013.03.001
Schulthess, B. et al. Evaluation of the Bruker MALDI biotyper for identification of fastidious Gram-negative rods. J. Clin. Microbiol. 54, 543–548 (2016).
pubmed: 26659214
pmcid: 4767947
doi: 10.1128/JCM.03107-15
Suto, C., Morinaga, M., Yagi, T., Tsuji, C. & Toshida, H. Conjunctival sac bacterial flora isolated prior to cataract surgery. Infect. Drug. Resist. 5, 37–41 (2012).
pubmed: 22294861
pmcid: 3269131
Reichert, R. & Stern, G. Quantitative Adherence of bacteria to human corneal epithelial cells. Arch. Ophthal. 102, 1394–1395 (1984).
pubmed: 6433864
doi: 10.1001/archopht.1984.01040031136041
Reichert, R. W., Das, N. D. & Zam, Z. S. Adherence properties of Pseudomonas pili to epithelial cells of the human cornea. Curr. Eye Res. 2, 289–293 (1982).
pubmed: 6131795
doi: 10.3109/02713688209000772
Marrs, C. F. & Weir, S. Pili (fimbriae) of Branhamella species. Am. J. Med. 88, 36s–40s (1990).
pubmed: 1971156
doi: 10.1016/0002-9343(90)90260-K
Tønjum, T., Marrs, C. F., Rozsa, F. & Bøvre, K. The type 4 pilin of Moraxella nonliquefaciens exhibits unique similarities with the pilins of Neisseria gonorrhoeae and Dichelobacter nodosus (Bacteroides). J. Gen. Microbiol. 137(2483), 2490 (1991).
Fernández, L. A. & Berenguer, J. Secretion and assembly of regular surface structures in Gram-negative bacteria. FEMS Microbiol. Rev. 24, 21–44 (2000).
pubmed: 10640597
doi: 10.1016/S0168-6445(99)00026-1
Waksman, G. & Hultgren, S. J. Structural biology of the chaperone-usher pathway of pilus biogenesis. Nat. Rev. Microbiol. 7, 765–774 (2009).
pubmed: 19820722
pmcid: 3790644
doi: 10.1038/nrmicro2220
Soto, G. E. & Hultgren, S. J. Bacterial adhesins: Common themes and variations in architecture and assembly. J. Bacteriol. 181, 1059–1071 (1999).
pubmed: 9973330
pmcid: 93481
doi: 10.1128/JB.181.4.1059-1071.1999
Monnier, V. M. & Cerami, A. Nonenzymatic browning in vivo: Possible process for aging of long-lived proteins. Science 211, 491–493 (1981).
pubmed: 6779377
doi: 10.1126/science.6779377
Kaji, Y. et al. Advanced glycation end products in Descemet’s membrane and their effect on corneal endothelial cell. Curr. Eye. Res. 23, 469–477 (2001).
pubmed: 12045898
doi: 10.1076/ceyr.23.6.469.6968
Marion, M. S. & Carlson, E. C. Immunoelectron microscopic analyses of maillard reaction products in bovine anterior lens capsule and Descemet’s membrane. Biochim. Biophys. Acta 1191, 33–42 (1994).
pubmed: 8155682
doi: 10.1016/0005-2736(94)90230-5
Metz, T. O., Alderson, N. L., Thorpe, S. R. & Baynes, J. W. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: A novel therapy for treatment of diabetic complications. Arch. Biochem. Biophys. 419, 41–49 (2003).
pubmed: 14568007
doi: 10.1016/j.abb.2003.08.021
Stitt, A. et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51, 2826–2832 (2002).
pubmed: 12196477
doi: 10.2337/diabetes.51.9.2826
Wu, K. K. & Huan, Y. Streptozotocin-induced diabetic models in mice and rats. Curr. Protoc. Ppharmacol. 40, 41–45 (2008).
Liang, X. & Ji, Y. Comparative analysis of staphylococcal adhesion and internalization by epithelial cells. Methods Mol. Biol. 391, 145–151 (2007).
pubmed: 18025675
doi: 10.1007/978-1-59745-468-1_11
Suzuki, T., Swoboda, J. G., Campbell, J., Walker, S. & Gilmore, M. S. In vitro antimicrobial activity of wall teichoic acid biosynthesis inhibitors against Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55, 767–774 (2011).
pubmed: 21098254
doi: 10.1128/AAC.00879-10
Suzuki, T. et al. Role of pvdE pyoverdine synthesis in pseudomonas aeruginosa keratitis. Cornea 37, S99–S105 (2018).
pubmed: 30252682
doi: 10.1097/ICO.0000000000001728